Press Release: European Medicines Agency informs doctors and patients about drug interaction between Victrelis and ritonavir-boosted HIV protease inhibitors

Author (Corporate)
Series Title
Series Details EMA/CHMP/119622/2012 (16.2.12)
Publication Date 16/02/2012
Content Type

The European Medicines Agency (EMA), in February 2012, recommended updating the prescribing information for Victrelis (boceprevir) with information about drug interactions between this hepatitis C medicine and the ritonavir-boosted HIV protease inhibitors atazanavir, darunavir and lopinavir.
Source Link http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/02/news_detail_001444.jsp&mid=WC0b01ac058004d5c1&murl=menus/news_and_events/news_and_events.jsp&jsenabled=true
Related Links
EMA: Press Release: EMA/CHMP/119622/2012 (16.2.12): European Medicines Agency informs doctors and patients about drug interaction between Victrelis and ritonavir-boosted HIV protease inhibitors http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/02/WC500122880.pdf
Subject Categories
Countries / Regions